SAN DIEGO, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) securities between October 31, 2023 and July 1, 2024. Ardelyx is a biotechnology company focused on developing and commercializing therapies for, among other things, patients with chronic kidney disease (“CKD”). For more information, submit a form, email attorney Aaron Dumas, Jr., or give us ...